Gilead Sciences Files 2024 10-K

Ticker: GILD · Form: 10-K · Filed: Feb 28, 2025 · CIK: 882095

Sentiment: neutral

Topics: 10-K, annual-report, biotech

TL;DR

Gilead dropped its 2024 10-K. Check financials & risks.

AI Summary

Gilead Sciences, Inc. filed its 2024 10-K on February 28, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Foster City, California, operates in the biological products sector. This filing provides a comprehensive overview of its financial performance, business operations, and risk factors for the period.

Why It Matters

This 10-K filing is crucial for investors and analysts to understand Gilead's financial health, strategic direction, and potential risks as of the end of the 2024 fiscal year.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Gilead faces inherent risks related to drug development, regulatory approvals, market competition, and patent expirations.

Key Numbers

Key Players & Entities

FAQ

What is Gilead Sciences' primary business classification?

Gilead Sciences, Inc. is classified under the Standard Industrial Classification code 2836 for Biological Products (no diagnostic substances).

When was the company's fiscal year end?

The company's fiscal year ends on December 31st.

What is the SEC file number for Gilead Sciences?

The SEC file number for Gilead Sciences is 000-19731.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered at 333 Lakeside Dr, Foster City, CA 94404.

What is the accession number for this 10-K filing?

The accession number for this 10-K filing is 0000882095-25-000006.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 28, 2025 regarding GILEAD SCIENCES, INC. (GILD).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing